Drug Profile
Apomorphine intranasal - Britannia
Latest Information Update: 09 Apr 2021
Price :
$50
*
At a glance
- Originator Britannia Pharmaceuticals
- Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Quinolines; Small molecules
- Mechanism of Action Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Erectile dysfunction; Parkinson's disease
Most Recent Events
- 02 Oct 2020 Britannia Pharmaceuticals has been acquired by STADA Arzneimittel
- 15 Jul 2019 Discontinued - Phase-I for Erectile dysfunction in United Kingdom (Intranasal)
- 15 Jul 2019 Discontinued - Phase-III for Parkinson's disease in United Kingdom (Intranasal)